Eupraxia stock Archives

ive professionals meet around a conference table with laptops and calendars, beside a whiteboard highlighting December EoE data and EPRX.

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. 5 days ago 281Views 0Likes

With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery. Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…

Vintage comic-style illustration of three bulls pulling a loaded wagon through sunny farmland, with “EPRX” and “Trio of Bulls” above.

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. October 12, 2026 662Views 0Likes

Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 587Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

by John F. Heerdink, Jr. August 11, 2026 284Views 0Likes

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) offer investors two distinctly attractive versions of the same biotech proposition: value creation through disciplined execution. Jazz is deploying capital to deepen an established rare-epilepsy franchise, while Eupraxia is assembling the…

Tag: Eupraxia stock

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Biotech’s Bullish Blueprint: Jazz Pharmaceuticals Buys Actio For ~$1.3B, While Eupraxia Builds for Scale -( $EPRX $JAZZ $XBI )

Your Guide To Staying Informed In The Markets